Circulating Tumor DNA-Guided Minimal Residual Disease Assessment in Colorectal Cancer
Pharmacogenomics · 2023
DOI: 10.2217/pgs-2022-0170 ↗Kurz gefasst
Editorial in der Zeitschrift Pharmacogenomics, 2023. Verfasst von Sakti Chakrabarti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Colorectal Neoplasms. Die Arbeit nennt 25 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
ORCID-Profile: Sakti Chakrabarti, Amit Mahipal
Zitieren
APA
Chakrabarti, S., & Mahipal, A. (2023). Circulating Tumor DNA-Guided Minimal Residual Disease Assessment in Colorectal Cancer. Pharmacogenomics. https://doi.org/10.2217/pgs-2022-0170
Vancouver
Chakrabarti S, Mahipal A. Circulating Tumor DNA-Guided Minimal Residual Disease Assessment in Colorectal Cancer. Pharmacogenomics. 2023. doi:10.2217/pgs-2022-0170
BibTeX
@article{Chakrabarti2023,
author = {Chakrabarti, Sakti and Mahipal, Amit},
title = {Circulating Tumor DNA-Guided Minimal Residual Disease Assessment in Colorectal Cancer},
journal = {Pharmacogenomics},
year = {2023},
doi = {10.2217/pgs-2022-0170}
}
EUVIMED